natgillin/translations-raw huggingface dataset:
Pregnancy and Fertility: Do not use on pregnant dogs and breeding dogs. 
Ne primjenjivati na gravidnim psima i psima za rasplod.
Activyl 100 mg spot-on for dogs 1.5 - 6.5 kg Activyl 150 mg spot-on for dogs 6.6 - 10 kg Activyl 300 mg spot-on for dogs 10.1 - 20 kg Activyl 600 mg spot-on for dogs 20.1 - 40 kg Activyl 900 mg spot-on for dogs 40.1 - 60 kg indoxacarb 
Activyl 100 mg spot on za pse 1,5 - 6,5 kg Activyl 150 mg spot on za pse 6,6 - 10 kg Activyl 300 mg spot on za pse 10,1-20 kg Activyl 600 mg spot on za pse 20,1 - 40 kg Activyl 900 mg spot on za pse 40,1 - 60 kg indoksakarb
Care should be taken to avoid the product coming into contact with the eyes of the cat. 
Treba paziti da se izbjegne doticaj s očima mačke.
The following table defines the size of pipette to be used according to the weight of the dog: 
U slijedećoj tablici definirane su veličine pipeta koja će se koristiti prema težini psa:
Spot-on use 
Spot on primjena
Activyl for very small dogs (1.5 - 6.5 kg) Activyl for small dogs (6.6 - 10 kg) Activyl for medium dogs (10.1 - 20 kg) Activyl for large dogs (20.1 - 40 kg) Activyl for extra large dogs (40.1 - 60 kg) 
Activyl za jako male pse (1,5 - 6,5 kg) Activyl za male pse (6,6 - 10 kg) Activyl za srednje pse (10,1 - 20 kg) Avtivyl za velike pse (20,1 - 40 kg) Activyl za iznimno velike pse (40,1 - 60 kg)
Care should be taken to avoid the product coming into contact with the eyes of the dog. 
Treba paziti da sadržaj pipete ili primijenjene doze ne dođe u dodir s očima psa.
Lactation: Do not use during lactation. 
Ne primjenjivati tijekom laktacije.
Dosage schedule: 
Plan primjene:
The following table defines the size of pipette to be used according to the weight of the cat: 
U slijedećoj tablici definirane su veličine pipeta koja će se koristiti prema težini mačke:
Ensure that the dosage (pipette) corresponds to the weight of the treated cat (see section 4.9). 
Osigurati da doza (pipete) odgovara težini tretirane mačke (vidjeti pod 4.9)
PACKAGE LEAFLET Activyl spot-on solution for cats 
UPUTA O VMP Activyl spot on otopina za mačke
indoxacarb 
indoksakarb
VIRBAC Ltd, Suffolk IP30 9 UP - UK, Tel: + 44 (0) 1359 243243 
VIRBAC Ltd, Suffolk IP30 9 UP - UK,
This product is for skin application on dogs only. 
Ovaj proizvod je za samo za vanjsku aplikaciju na psu.
VIRBAC BELGIUM NV, 
VIRBAC France,
Pulawska 314, PL-02 819 Warszawa, Tel.: + 48 22 855 40 46 
Z O.O., Ul. Pulawska 314, PL-02 819 Warszawa,
In very rare cases, application site reactions such as transitory scratching, erythema (redness of skin), alopecia (loss of hair) or dermatitis (inflammation of the skin) at the application site may occur. 
U vrlo rijetkim slučajevima na mjestu aplikacije može doći do prolaznog grebanja, eritema (crvenilo kože), alopecije (gubitak dlake) ili dermatitisa (upala kože) na mjestu primjene.
One unit-dose pipette delivers: 
Jedna pipeta s jediničnom dozom sadrži:
DE-22843 Bad Oldesloe, Tel: + 49 (4531) 805 111 
Tel: + 49 (4531) 805 111
Activyl 100 mg spot-on solution for small cats (≤ 4 kg) Activyl 200 mg spot-on solution for large cats (> 4 kg) 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Activyl 100 mg spot on otopina za male mačke (≤ 4 kg) Activyl 200 mg spot on otopina za velike mačke (˃ 4 kg)
In rare cases, application site reactions such as transitory scratching, erythema, alopecia or dermatitis at the application site may occur. 
U rijetkim slučajevima mogu se desiti reakcije kao što su prolazno grebanje, eritem, alopecija ili dermatitis na mjestu primjene.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
NOSITELJ(I) ODOBRENJA ZA PROIZVODNJU ODGOVORAN(I) ZA PUŠTANJE SERIJE U PROMET
Activyl 100 mg spot-on for very small dogs Activyl 150 mg spot-on for small dogs Activyl 300 mg spot-on for medium dogs Activyl 600 mg spot-on for large dogs Activyl 900 mg spot-on for extra large dogs indoxacarb 
Activyl 100 mg spot on otopina za jako male pse Activyl 150 mg spot on otopina za male pse Activyl 300 mg spot on otopina za srednje pse Activyl 600 mg spot on otopina za velike pse Activyl 900 mg spot on otopine za iznimno velike pse indoksakarb
Activyl 100 mg spot-on solution for very small dogs (1.5 - 6.5 kg) Activyl 150 mg spot-on solution for small dogs (6.6 - 10 kg) Activyl 300 mg spot-on solution for medium dogs (10.1 - 20 kg) Activyl 600 mg spot-on solution for large dogs (20.1 - 40 kg) Activyl 900 mg spot-on solution for extra large dogs (40.1 - 60 kg) 
Activyl 100 mg spot on otopina za jako male pse ( 1,5 - 6,5 kg) Activyl 150 mg spot on otopina za male pse (6,6 - 10 kg) Activyl 300 mg spot on otopina za srednje pse (10,1 - 20 kg) Activyl 600 mg spot on otopina za velike pse (20,1 - 40 kg) Activyl 900 mg spot on otopine za jako velike pse (40,1 - 60 kg)
In rare cases, application site reactions such as transitory scratching, erythema (redness of skin), alopecia (loss of hair) or dermatitis (inflammation of the skin) at the application site may occur. 
U rijetkim slučajevima može doći do prolaznog grebanja, eritema (crvenila kože) , alopecije (gubitka dlake) ili dermatitisa (upale kože) na mjestu primjene.
Activyl 100 mg for very small dogs Activyl 150 mg for small dogs 10.1 - 20 Activyl 300 mg for medium dogs 20.1 - 40 Activyl 600 mg for large dogs 40.1 - 60 Activyl 900 mg for extra large dogs The appropriate combination of pipettes should be used 
1,5 - 6,5 Activyl 100 mg za jako male pse 6,6 - 10 Activyl 150 mg za male pse 10,1 - 20 Activyl 300 mg za srednje pse 20,1 - 40 Activyl 600 mg za velike pse 40,1 - 60 Activyl 900 mg za iznimno velike pse
Esperantolaan 4, BE-3001 Leuven, Tél/Tel: + 32 (0) 16 38 72 60 
Tél/Tel: + 32 (0) 16 38 72 60
Large cats 
Veličina pipete
VIRBAC BELGIUM NV, Esperantolaan 4, BE-3001 Leuven, Tél/Tel: + 32 (0) 16 38 72 60 
VIRBAC BELGIUM NV, Esperantolaan 4, BE-3001 Leuven,
Quinta da Beloura, PT-2710-693 Sintra, Tel: + 351 219 245 020 
PT-2710-693 Sintra,
Activyl 100 mg spot-on solution for very small dogs Activyl 150 mg spot-on solution for small dogs Activyl 300 mg spot-on solution for medium dogs Activyl 600 mg spot-on solution for large dogs Activyl 900 mg spot-on solution for extra large dogs 
Activyl 100 mg spot on otopina za jako male pse Activyl 150 mg spot on otopina za male pse Activyl 300 mg spot on otopina za srednje pse Avtivyl 600 mg spot on otopina za velike pse Activyl 900 mg spot on otopina za iznimno velike pse
Special precautions for use in animals: Ensure that the dosage (pipette) corresponds to the weight of the treated cat (see section 8). 
Osigurati da doza (pipeta) odgovara težini tretirane mačke (vidjeti odjeljak 8) Aplicirati na površinu netaknute kože.
PACKAGE LEAFLET Activyl spot-on solution for dogs 
Activyl spot-on otopina za pse
Activyl 100 mg spot-on for small cats Activyl 200 mg spot-on for large cats indoxacarb 
Activyl 200 mg spot on za velike mačke indoksakarb
Pipette size to be used 
Veličina pipete Volumen
Activyl 100 mg spot-on solution for small cats Activyl 200 mg spot-on solution for large cats indoxacarb 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Activyl 100 mg spot on otopina za male mačke Activyl 200 mg spot on otopina za velike mačke indoksakarb
Step 2: Part the hair until the skin is visible.Place the pipette tip against the skin at the base of the skull, where the cat cannot lick it off. 
Postavite pipetu na kožu na bazu lubanje gdje je mačkane može polizati.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Active substance: 
NAVOĐENJE DJELATNIH I DRUGIH TVARI
The sachet is child-resistant. 
Vrećica je zaštićena od otvaranja od strane djece.
Prevention of flu 
Prevencija gripe
Further information on Tamiflu can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/tamiflu. 
Više informacija o lijeku Tamiflu nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/tamiflu.
When the neuramidases are blocked, the virus cannot spread. 
Ako su neuraminidaze inhibirane, virus se ne može širiti.
Treatment of flu 
Liječenje gripe
The average reduction in the duration of the illness in children aged 1 to 6 years was 1.5 days. 
Prosječno smanjenje trajanja bolesti u djece u dobi od jedne do 6 godina iznosilo je 1,5 dana.
Side effects are generally mild or moderate in severity. 
Nuspojave su većinom blage ili umjerene.
Effectiveness was measured by recording symptoms (feeling feverish, muscle pain, headache, sore throat, cough, overall discomfort and runny nose). 
Učinkovitost je mjerena bilježenjem simptoma (osjećaj vrućice, bol u mišićima, glavobolja, grlobolja, kašalj, sveukupni osjećaj nelagode i curenje nosa).
The studies measured the number of cases of flu proven by laboratory tests. 
U ispitivanjima se pratio broj slučajeva gripe potvrđenih laboratorijskim nalazima.
Tamiflu cannot replace flu vaccination, and its use should be based on official recommendations. 
Tamiflu ne može zamijeniti cjepivo protiv gripe i njegova primjena treba se temeljiti na službenim preporukama.
Tamiflu can also be used as preventative treatment in exceptional cases, for instance when the seasonal flu vaccine may not provide sufficient protection and when there is a pandemic (a global epidemic of flu). 
Lijek Tamiflu može se primjenjivati i kao preventivna terapija u iznimnim slučajevima, primjerice ako sezonsko cjepivo protiv gripe možda ne pruža dovoljnu zaštitu i ako vlada pandemija (globalna epidemija gripe).
Tamiflu received a marketing authorisation valid throughout the EU on 20 June 2002. 
Lijek Tamiflu dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 20. lipnja 2002.
Tamiflu is available as capsules (30 mg, 45 mg, and 75 mg) and as a powder that is made up into a liquid to be drunk (6 mg/ml and 12 mg/ml). 
Tamiflu je dostupan u obliku kapsula (30 mg, 45 mg i 75 mg) i u prahu od kojeg se priprema tekućina za oralnu primjenu (6 mg/ml i 12 mg/ml).
What measures are being taken to ensure the safe and effective use of Tamiflu? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Tamiflu?
In adults, the duration of the illness was reduced from an average of 5.2 days for patients taking placebo, to 4.2 days for patients taking Tamiflu. 
U odraslih je osoba trajanje bolesti skraćeno s prosječnih 5,2 dana za bolesnike koji uzimaju placebo na 4,2 dana za bolesnike koji uzimaju Tamiflu.
The medicine contains the active substance oseltamivir. 
Lijek sadrži djelatnu tvar oseltamivir.
The usual dose for adults and children weighing more than 40 kg is 75 mg given once a day for at least 10 days after contact with an infected person. 
Uobičajena doza za odrasle osobe i djecu tjelesne težine veće od 40 kg iznosi 75 mg jedanput na dan tijekom najmanje 10 dana nakon kontakta sa zaraženom osobom.
Side effects reported with Tamiflu are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Tamiflu pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
It can also reduce the incidence of flu in patients who had come into contact with the disease or during a pandemic. 
Lijek isto tako može smanjiti incidenciju gripe u bolesnika koji su bili u kontaktu s bolešću ili tijekom pandemije.
A study also looked at using Tamiflu in a family setting (277 families) for both the treatment of the person with flu, and the treatment or prevention of flu in those in contact with the person. 
U ispitivanju se također promatrala primjena lijeka Tamiflu u obiteljskom okruženju (277 obitelji) za liječenje osobe zaražene gripom, ali i liječenje ili prevenciju gripe u osoba koje su u kontaktu s tom osobom.
Tamiflu reduced the incidence of flu in people who had come into contact with the disease when one of their family members contracted flu (962 cases) or during an epidemic (1,562 people aged between 16 and 65 years, and 548 elderly people in nursing homes). 
Lijek Tamiflu smanjio je incidenciju gripe u osoba koje su bile u kontaktu s bolešću ako je jedan član njihove obitelji zaražen gripom (962 slučaja) ili tijekom epidemije (1 562 osobe u dobi između 16 i 65 godina i 548 starije osobe u domovima za starije i nemoćne osobe).
Tamiflu is an antiviral medicine used to treat or prevent influenza (flu). 
Tamiflu je antivirusni lijek za liječenje ili prevenciju influence (gripe):
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tamiflu have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Tamiflu nalaze se u sažetku opisa svojstava i u uputi o lijeku.
Oseltamivir works on the neuramidases of both influenza A (the most common type) and influenza B viruses. 
Oseltamivir djeluje na neuraminidaze oba virusa, influence A (najčešćeg tipa) i influence B.
When used for treatment of flu, Tamiflu reduces the duration of illness in adults and children. 
Kada se primjenjuje u liječenju gripe, lijek Tamiflu skraćuje trajanje bolesti u odraslih osoba i djece.
In families with one patient who had flu, 7% of the family members in the household developed flu when receiving Tamiflu, compared with 20% of those receiving no preventative treatment. 
U obiteljima u kojima je jedan bolesnik imao gripu, 7 % članova obitelji u kućanstvu dobilo je gripu nakon uzimanja lijeka Tamiflu, u usporedbi s 20 % osoba koje nisu uzimale preventivnu terapiju.
• to treat flu, it can be used in adults and children (including full-term newborns) who have the symptoms of flu, when the flu virus is circulating in the community; 
• u svrhu liječenja gripe primjenjuje se u odraslih osoba i djece (uključujući novorođenčad rođenu na vrijeme) koji imaju simptome gripe, kada se virus gripe širi u zajednici;
In the study carried out during an epidemic, 1% of the people taking Tamiflu developed flu after contact, compared with 5% of those taking placebo. 
U ispitivanju provedenom tijekom epidemije, 1 % osoba koje su uzimale Tamiflu dobilo je gripu nakon kontakta, u usporedbi s 5 % onih koji su uzimali placebo.
Tamiflu reduced the duration of the illness compared with placebo (a dummy treatment) in several studies (involving 2,413 patients aged 13 years or over, 741 elderly patients aged 65 years or over and 1,033 children aged between 1 and 12 years). 
Lijek Tamiflu skratio je trajanje bolesti u usporedbi s placebom (prividno liječenje) u nekoliko ispitivanja (na 2 413 bolesnika u dobi od 13 godina i starijih, 741 starijeg bolesnika u dobi od 65 godina ili starijih i u 1 033 djece u dobi između jedne godine i 12 godina).
Why is Tamiflu authorised in the EU? 
Zašto je Tamiflu odobren u EU-u?
As for all medicines, data on the use of Tamiflu are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Tamiflu kontinuirano se prate.
What is Tamiflu and what it is used for? 
Što je Tamiflu i za što se primjenjuje?
When Tamiflu is used during a flu epidemic, it is given for up to 6 weeks. 
Ako se Tamiflu primjenjuje tijekom epidemije gripe, može se primjenjivati do šest tjedana.
The European Medicines Agency decided that Tamiflu's benefits are greater than its risks and recommended that it can be authorised for use in the EU. 
Europska agencija za lijekove zaključila je da koristi od lijeka Tamiflu nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
Other information about Tamiflu 
Ostale informacije o lijeku Tamiflu
During a flu pandemic, Tamiflu can also be used to prevent flu in babies below 1 year of age. 
Tijekom pandemije gripe, Tamiflu se može primjenjivati i za prevenciju gripe kod beba mlađih od godinu dana.
The active substance in Tamiflu, oseltamivir, acts on the flu virus, blocking some of the enzymes on its surface known as neuramidases. 
Djelatna tvar lijeka Tamiflu, oseltamivir, djeluje na virus gripe tako da inhibira neuraminidaze, određene enzime na njegovoj površini.
For more information about using Tamiflu, see the package leaflet or contact your doctor or pharmacist. 
Više informacija o primjeni lijeka Tamiflu pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
The most common side effects with Tamiflu (seen in more than 1 patient in 10) in adults and adolescents are headache and nausea (feeling sick). 
Najčešće nuspojave povezane s lijekom Tamiflu (zabilježene u više od 1 na 10 bolesnika) u odraslih osoba i adolescenata jesu glavobolja i mučnina (slabost).
What are the risks associated with Tamiflu? 
Koji su rizici povezani s lijekom Tamiflu?
• to prevent flu, it can be used in adults and children over 1 year of age who have been in contact with someone who has flu and flu is circulating in the community. 
• radi prevencije gripe može se primjenjivati u odraslih osoba i djece starije od jedne godine koji su bili u kontaktu s osobom oboljelom od gripe i ako u zajednici kruži gripa.
In children the most common side effects (seen in more than 1 patient in 10) are vomiting, cough and nasal congestion (a blocked nose). 
Najčešće nuspojave u djece (zabilježene u više od 1 na 10 bolesnika) jesu povraćanje, kašalj i nazalna kongestija (začepljenost nosa).
An overview of Tamiflu and why it is authorised in the EU 
Pregled informacija o lijeku Tamiflu i zašto je odobren u EU-u
In the prevention of flu, Tamiflu must be started within two days of contact with someone who has flu. 
Za prevenciju gripe terapiju lijekom Tamiflu treba započeti unutar dva dana od kontakta s osobom koja ima gripu.
In the treatment of flu, Tamiflu must be started within two days of the onset of symptoms. 
Tijekom liječenja gripe primjenu lijeka Tamiflu treba započeti unutar dva dana od nastupa simptoma.
What benefits of Tamiflu have been shown in studies? 
Koje su koristi od lijeka Tamiflu utvrđene u ispitivanjima?
How does Tamiflu work? 
Kako djeluje Tamiflu?
For the full list of side effects and restrictions with Tamiflu, see the package leaflet. 
Potpuni popis nuspojava i ograničenja pri primjeni lijeka Tamiflu potražite u uputi o lijeku.
This is generally done on a caseby-case basis. 
Primjena lijeka u načelu ovisi o pojedinačnom slučaju.
How is Tamiflu used? 
Kako se Tamiflu primjenjuje?
Patients can inject the medicine themselves after being trained. 
Bolesnici si mogu sami ubrizgavati lijek nakon što prođu odgovarajuću obuku.
Further information on Aimovig can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/aimovig. 
Više informacija o lijeku Aimovig nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/aimovig.
Aimovig received a marketing authorisation valid throughout the EU on 26 July 2018. 
Lijek Aimovig dobio je odobrenje za stavljanje u promet koje je na snazi na prostoru EU-a od 26. srpnja 2018.
The recommended dose is 70 mg every 4 weeks as a single injection. 
Preporučena doza je 70 mg svaka četiri tjedna u obliku jedne injekcije.
Most of the side effects are mild or moderate in severity. 
Većina nuspojava bila je blage ili umjerene težine.
Some patients may benefit from a dose of 140 mg every 4 weeks, given as either a single injection of 140 mg or two injections of 70 mg. 
Neki bolesnici mogu imati koristi od doze od 140 mg svaka četiri tjedna koja se primjenjuje ili kao jednokratna injekcija od 140 mg ili kao dvije injekcije od 70 mg.
What is Aimovig and what is it used for? 
Što je Aimovig i za što se koristi?
What measures are being taken to ensure the safe and effective use of Aimovig? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Aimovig?
Aimovig can only be obtained with a prescription and treatment should be started by a doctor experienced in the diagnosis and treatment of migraine. 
Aimovig se izdaje samo na liječnički recept, a liječenje mora započeti liječnik s iskustvom u dijagnosticiranju i liječenju migrene.
Side effects reported with Aimovig are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Aimovig pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
The most common side effects with Aimovig (which may affect up to 1 in 10 people) are reactions at the site of injection, constipation, muscle spasms and itching. 
Najčešće nuspojave lijeka Aimovig (koje se mogu javiti u najviše 1 na 10 osoba) su reakcije na mjestu injekcije, zatvor, grčevi u mišićima i svrbež.
By attaching to this receptor, the medicine stops CGRP from attaching to it and causing migraine. 
Vezivanjem na taj receptor lijek onemogućuje da se na njega veže CGRP i izazove migrenu.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aimovig have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Aimovig nalaze se u sažetku opisa svojstava i u uputi o lijeku.
The European Medicines Agency therefore decided that Aimovig's benefits are greater than its risks and it can be authorised for use in the EU. 
Europska agencija za lijekove stoga je zaključila da koristi od lijeka Aimovig nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
Other information about Aimovig 
Ostale informacije o lijeku Aimovig
The active substance in Aimovig, erenumab, is a monoclonal antibody (a type of protein) designed to attach to a receptor (target) for CGRP on body's cells. 
Djelatna tvari lijeka Aimovig, erenumab, monoklonsko je protutijelo (vrsta bjelančevine) osmišljeno za vezivanje na receptor (cilj) za CGRP na stanicama u tijelu.
Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. 
Aimovig je lijek koji se primjenjuje za sprječavanje migrene u odraslih osoba koje imaju migrenu najmanje četiri dana mjesečno.
As for all medicines, data on the use of Aimovig are continuously monitored. 
Kao za sve lijekove, podatci o primjeni lijeka Aimovig kontinuirano se prate.
An overview of Aimovig and why it is authorised in the EU 
Pregled informacija o lijeku Aimovig i zašto je odobren u EU-u
What are the risks associated with Aimovig? 
Koji su rizici povezani s lijekom Aimovig?
Aimovig (erenumab) EMA/CHMP/249688/2019 
Aimovig (erenumab) EMA/191978/2019
Aimovig is injected under the skin using a pre-filled syringe or pen. 
Aimovig se ubrizgava pod kožu s pomoću napunjene štrcaljke ili brizgalice.
Why is Aimovig authorised in the EU? 
Zašto je lijek Aimovig odobren u EU-u?
In a second study of 955 patients who had migraines 8 days a month on average, those treated with Aimovig had on average 3 to 4 fewer days with migraines per month compared with around 2 fewer days for patients on placebo. 
U drugom ispitivanju koje je obuhvatilo 955 bolesnika koji su u prosjeku imali migrenu osam dana mjesečno, bolesnici liječeni lijekom Aimovig iskusili su u prosjeku tri do četiri dana s migrenom manje, u usporedbi s otprilike dva dana manje u bolesnika koji su primali placebo.
How is Aimovig used? 
Kako se Aimovig koristi?
For more information about using Aimovig, see the package leaflet or contact your doctor or pharmacist. 
Više informacija o primjeni lijeka Aimovig pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
In a study of 667 patients who had migraines 18 days a month on average, those treated with Aimovig had 7 fewer days with migraines per month, compared with 4 fewer days for patients on placebo. 
U ispitivanju koje je obuhvatilo 667 bolesnika koji su u prosjeku imali migrenu 18 dana mjesečno, bolesnici liječeni lijekom Aimovig iskusili su sedam dana s migrenom manje, u usporedbi s četiri dana manje u bolesnika koji su primali placebo.
A chemical messenger called CGRP has been shown to be involved in the development of migraine. 
Dokazano je da je u nastajanje migrene uključen kemijski glasnik naziva CGRP.
Only patients with migraines at least 4 days a month were included in the studies as patients with less frequent migraines are not usually eligible for preventative treatment. 
Ispitivanja su obuhvatila samo bolesnike koji imaju migrenu najmanje četiri dana mjesečno jer preventivno liječenje uglavnom nije prikladno u bolesnika u kojih su migrene rjeđe.